Rapid Generation of High Antibody-producer Clones Utilizing Selexis’ SURE Technology Platform
Selexis SA to Present at the European Cell Line Development and Engineering Conference
Geneva, Switzerland – May 5, 2006 - Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic protein manufacturing announced today that it will present “Rapid Generation of High Antibody-producer Clones with MARtech™” at the next European Cell Line Development and Engineering Conference in Zurich, Switzerland (May 23-24, 2006).
Dr. Pierre-Alain, Ph.D., Head of Research and Development at Selexis, will present on Tuesday, May 23, 2006 at 16:40 as part of the “Vector Development and Gene Optimization” track. Selected slides from the lecture, including data on the SURE Technology Platform, which includes the patented MARtech™, will also be available following the meeting.
Presentation Abstract
Rapid generation of high antibody-producer clones with MARtech™
The development of high producer cell lines for manufacturing of recombinant proteins requires
the identification of rare clones with defined specificities. We have developed a method that
allows the rapid generation of highly productive cell lines that express recombinant human IgG
with productivities >50 pcd by placing a MAR element in the vectors. MARtech has the potential
to increase stability and proves valuable to shorten the timelines of the selection process.
Selexis’ SURE Technology Platform, which includes the patented MARtech™, is a unique technology that improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. Based on proprietary human MAR (Matrix Attachment Region), MARtech™ enables cell population generation in just four weeks (after transfection) and stable cell line development in ten weeks (after transfection to first round of cell cloning). Additionally, MARtech™ has been found to significantly increase recombinant protein expression in mammalian cells in suspension and in serum-free up to twenty fold.
About Selexis
Headquartered in Geneva, Switzerland, Selexis is a privately held biotechnology company
dedicated to the development of innovative technologies and expert services. Selexis offers
comprehensive and rapid solutions for the development of stable, high yield mammalian cell lines
used in recombinant protein manufacturing.. The Company’s unique SURE Technology Platform,
which includes Selexis’ forth generation patented MARtech™, reduces traditional cell line
development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones)
without any change in the scale-up process. For more information please visit
http://www.selexis.com
About IBC Life Sciences, “Antibody Development and Production” Conference
IBC's pioneering European Cell Line Development and Engineering Conference is the first forum
in Europe dedicated exclusively to optimizing cell lines, covering the following topics in detail:
Keynote presentations and forward thinking studies by experts from academia and industry;
Specific case study examples on current 'best practices' approach to cell line development,
choice of host cells, expression system, selection strategies, etc. Interactive discussion session
will compare and contrast the different strategies; An in-depth session on cell line validation and
regulatory considerations; New reports on optimising expression vector design and translation;
An in-depth session on screening and clone selection methods; and End users’ comparative
evaluation on current most popular technologies. For more information, please visit :
http://www.ibc-lifesci.com/celldev/default.asp?src=forthnew